Biogen Unternehmensprofil | finanzen.ch
SMI 11’263 0.6%  SPI 14’398 0.7%  Dow 34’201 0.5%  DAX 15’460 1.3%  Euro 1.1029 -0.1%  EStoxx50 4’033 1.0%  Gold 1’783 1.1%  Bitcoin 56’969 -2.3%  Dollar 0.9201 -0.2%  Öl 66.7 -0.2% 

Aktionärsstruktur

Inhaber in %
Freefloat 99.79
PRIMECAP Management Co. 10.28
The Vanguard Group, Inc. 7.73
Vanguard Group, Inc. (Subfiler) 7.29
Vanguard PRIMECAP Fund 5.76
State Street Corp. 4.54
Wellington Management Co. LLP 3.76
BlackRock Fund Advisors 3.27
Vanguard Total Stock Market Index Fund 2.85
Vanguard Health Care Fund 2.74
BlackRock Institutional Trust Co. NA 2.37
ClearBridge Investments LLC 2.34
Vanguard 500 Index Fund 2.06
Renaissance Technologies LLC 1.97
Geode Capital Management LLC 1.79

*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.

Personal

2016 2017 2018 2019 2020
Personal am Ende des Jahres 7’400 7’300 7’800 7’400 9’100
Umsatz pro Mitarbeiter in Mio. EUR 1.38 1.51 1.55 1.72 1.36

Bilanz (in Mio. EUR) - Aktiva

2016 2017 2018 2019 2020
Summe Umlaufvermögen 8’732 7’873 7’641 8’382 6’887
Summe Anlagevermögen 18’658 18’551 18’976 19’784 18’612
Summe Aktiva 22’877 23’653 25’289 27’234 24’619

Bilanz (in Mio. EUR) - Passiva

2016 2017 2018 2019 2020
Gesamtverschuldung/ -verbindlichkeiten 6’517 5’938 5’937 6’441 7’911
Summe Fremdkapital 10’748 11’055 12’257 13’895 13’933
Summe Eigenkapital 12’129 12’598 13’032 13’339 10’686
Summe Passiva 22’877 23’653 25’289 27’234 24’619

Adresse

225 Binney Street, 02142 Cambridge
Telefon +1 (617) 679-2000
URL http://www.biogen.com

Management

Alexander John Denner
Independent Director
Alfred W. Sandrock
Executive Vice President-Research & Development
Alphonse Galdes
EVP-Pharmaceutical Operations & Technology
Anabella Villalobos
SVP-Biotherapeutic & Medicinal Sciences
Brian S. Posner
Independent Director
Caroline D. Dorsa
Independent Director
Chirfi Guindo
EVP-Global Product Strategy & Commercialization
Daniel Karp
Executive Vice President-Corporate Development
Eric K. Rowinsky
Independent Director
Ginger Gregory
Chief Human Resources Officer & Executive VP
Jacob Elkins
Vice President & Head-Acute Neurology Research
Jesus B. Mantas
Independent Director
Mahalakshmi Radhakrishnan
Chief Medical Officer & Group Senior VP
Mark Hernon
Chief Information Officer & Senior Vice President
Michael Dambach
Treasurer & Vice President
Michael R. McDonnell
Chief Financial Officer & Executive Vice President
Michel Vounatsos
Chief Executive Officer & Director
Mike Hencke
Director-Investor Relations
Nancy L. Leaming
Independent Director
Natacha Gassenbach
Chief Communication Officer
Richard Charles Mulligan
Independent Director
Robert W. Pangia
Independent Director
Robin C. Kramer
Chief Accounting Officer & Senior Vice President
Rohin Mhatre
Senior VP-Product & Technology Development
Stelios Papadopoulos
Chairman
Stephanie Dyson
Vice President-Public Policy & Government Affairs
Stephen A. Sherwin
Independent Director
Susan H. Alexander
Secretary, Chief Legal Officer & Executive VP
Suzanne E. Murray
Corporation Counsel & Assistant Secretary
William A. Hawkins
Independent Director

Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen